Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 605 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Functional Clear all

Conditions: Renal Impairment
Interventions: tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Renal Impairment
Interventions: OTAMIXABAN (XRP0673); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Miami Gardens, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more

Conditions: Albuminuria
Interventions: Montelukast, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Kidney Pancreas Transplantation
Interventions: Envarsus XR; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Transplant
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: Not listed
Enrollment: 3,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 5
States / cities: Birmingham, Alabama • Iowa City, Iowa • Minneapolis, Minnesota + 1 more

Conditions: Renal Impairment
Interventions: IXP; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Ocala, Florida • Tampa, Florida

Conditions: Hepatitis C
Interventions: DCV 3DAA FDC, BMS-791325; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Improve Endothelial Function and Decrease Vascular Stenosis
Interventions: Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 2 Diabetes, Chronic Kidney Disease
Interventions: Zemplar, Placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Boston, Massachusetts + 1 more

Conditions: Carnitine Ingestion
Interventions: Carnitine, Placebo; Dietary Supplement
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Renal Impairment
Interventions: Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL; Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 9 more

Conditions: Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions: Dapagliflozin 10 MG [Farxiga]; Drug
Lead sponsor: Emerald Clinical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions: BMS-986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida

Conditions: Kidney Transplant
Interventions: Administration of continuous insulin infusion for glycemic control in brain dead donors; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: End Stage Chronic Renal Failure, Chronic Kidney Disease (Stages 4 and 5), Kidney Transplantation Recipients
Interventions: 10˚C deceased donor kidney storage using Traferox XPort; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer
Interventions: Vismodegib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more

Conditions: Cardiovascular Diseases, Hypertension, Racism, Vascular Diseases
Interventions: MitoQ; Dietary Supplement
Lead sponsor: Auburn University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Renal Impairment
Interventions: HM15912; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more

Conditions: Obesity
Interventions: Qsymia, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Healthy Volunteer
Interventions: RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Liver Failure, Renal Failure
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Pneumonia
Interventions: CP-70,429 and PF-03709270; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Disease
Interventions: Apraglutide; Drug
Lead sponsor: VectivBio AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Orlando, Florida • Saint Paul, Minnesota

Conditions: Impaired Renal Function
Interventions: Aldafermin (NGM282); Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

A Study of Factors That Affect Long-Term Kidney Transplant Function

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease

Measurement of Renal Function With Iohexol in Subjects Ingesting Carnitine

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

Dapagliflozin Treatment in Type 2 Diabetes

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

Intensive Insulin Therapy in Deceased Donors

Deceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage

A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

Mitochondria Oxidative Stress and Vascular Health Study

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

Assessment of Renal Function in Cirrhotic Patients

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function